Lv21
152 积分 2024-04-10 加入
Rocatinlimab Improves Patient-Reported Outcomes in Adults with Moderate-to-Severe Atopic Dermatitis: Results from a Double-Blind Placebo-Controlled Phase 2b Study
23分钟前
待确认
Extended Half-life Antibodies: A Narrative Review of a New Approach in the Management of Atopic Dermatitis
1小时前
已完结
Safety and efficacy of amlitelimab, a fully human nondepleting, noncytotoxic anti-OX40 ligand monoclonal antibody, in atopic dermatitis: results of a phase IIa randomized placebo-controlled trial
2小时前
已完结
OX40L Inhibition Suppresses KLH-driven Immune Responses in Healthy Volunteers: A Randomized Controlled Trial Demonstrating Proof-of-Pharmacology for KY1005
16天前
已完结
Summary of Research: An Anti-OX40 Antibody to Treat Moderate-to-Severe Atopic Dermatitis: A Multicentre, Double-Blind, Placebo-Controlled Phase 2b Study
16天前
已完结
An anti-OX40 antibody to treat moderate-to-severe atopic dermatitis: a multicentre, double-blind, placebo-controlled phase 2b study
16天前
已完结
A Comprehensive Review of Biologics in Phase III and IV Clinical Trials for Atopic Dermatitis
17天前
已完结
A first-in-human, single and multiple dose study of lunsekimig, a novel anti-TSLP/anti-IL-13 NANOBODY® compound, in healthy volunteers
1个月前
已完结
The Epidemiology and Global Burden of Atopic Dermatitis: A Narrative Review
1个月前
已完结
皖公网安备34019202002308
